Showing results (171-180 of 283) with videos related to

Sort By:
Pageof 29
F1000Research|August 20, 2016
Robust de novo pathway enrichment with KeyPathwayMiner 5Nicolas Alcaraz, Markus List, Martin Dissing-Hansen, et al.
Genes|March 6, 2021
HMGA2 as a Critical Regulator in Cancer DevelopmentBehzad Mansoori, Ali Mohammadi, Henrik J Ditzel, et al.
Oncoimmunology|June 23, 2017
Downregulation of antigen presentation-associated pathway proteins is linked to poor outcome in triple-negative breast cancer patient tumorsMartin H Pedersen, Brian L Hood, Hans Christian Beck, et al.
Breast Cancer Research and Treatment|February 2, 2012
The miRNA-200 family and miRNA-9 exhibit differential expression in primary versus corresponding metastatic tissue in breast cancerKarina H Gravgaard, Maria B Lyng, Anne-Vibeke Laenkholm, et al.
The Journal of Experimental Medicine|September 30, 2018
KDM4B-regulated unfolded protein response as a therapeutic vulnerability in PTEN-deficient breast cancerWenyu Wang, Gokce Oguz, Puay Leng Lee, et al.
Oncogene|September 23, 2018
Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapyD Elias, H Vever, A-V Lænkholm, et al.
AIDS Research and Human Retroviruses|July 1, 1996
Human antibody responses to HIV type 1 glycoprotein 41 cloned in phage display libraries suggest three major epitopes are recognized and give evidence for conserved antibody motifs in antigen bindingJ M Binley, H J Ditzel, C F Barbas, et al.
Oncogene|June 3, 2014
Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapyD Elias, H Vever, A-V Lænkholm, et al.
Oncogene|November 13, 2019
Correction: Gene expression profiling identifies FYN as an important molecule in tamoxifen resistance and a predictor of early recurrence in patients treated with endocrine therapyD Elias, H Vever, A-V Lænkholm, et al.
Journal of Virology|April 29, 1998
Neutralization of human immunodeficiency virus type 1 by antibody to gp120 is determined primarily by occupancy of sites on the virion irrespective of epitope specificityP W Parren, I Mondor, D Naniche, et al.
Pageof 29